BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, signed a master service and technology agreement (MSTA) agreement with Prevail InfoWorks, Inc. (InfoWorks), a Philadelphia-based contract research organization (CRO), to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer.

Services include clinical site coordination, project management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWork’s integrated real-time data analytics platform, The Single Interface, for clinical support and real-time data analysis.

Prevail Partners, LLC, an investment fund, and affiliate of InfoWorks, has agreed to purchase 463,408 BriaCell common shares for $4 million.

“We have high confidence in Prevail InfoWorks’ ability to coordinate our pivotal clinical trial in advanced breast cancer,” said William Williams, BriaCell’s President & CEO. “They have extensive experience and expertise which should assure rapid accrual and smooth execution of the study. Additionally, fast, reliable data access is essential to successful and timely completion of our upcoming pivotal trial, lowers our clinical risk, and may speed up the FDA approval timeline,” stated. Prevail Partners’ strategic investment in BriaCell’s registration study further highlights the confidence Prevail has in our ability to execute on enrolment targets and subsequent survival data.”